Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market for myocardial ischemia is influenced by the growing prevalence of this condition, driven by factors such as sedentary lifestyles, unhealthy dietary habits, and an aging population. Increased awareness about the risks and symptoms of myocardial ischemia is contributing to early detection and intervention.
A peculiar trend is the steady evolution of diagnostic imaging techniques to identify myocardial ischemia. In the field of imaging technology, various innovations of imaging modalities, especially in the decoration of cardiac MRI, CT angiography, and nuclear imaging resulting to accurate detection and early discovery of ischemic events as a basis of providing capable treatment strategies.
Myocardial ischemia point-of-care testing is emerging. The recent emergence of rapid and on site diagnostic tools such as handheld troponin tests and handheld ECG devices have increased the speed of cardiac assessment as well as enabling quick intervention thus reduce the time to diagnosis.
Implementation of artificial intelligence plays a significant role in the diagnosis and treatment of myocardial ischemia. Data analysis is executed by AI algorithms to simplify complex data sets and assist with risk stratification and decision support, improving diagnostic and treatment planning precision and outcome.
Rising significance for particular treatment of myocardial ischemia is a trend associated with personalized medicine. Traditionally, therapies have been one-size-fits-all interventions, targeting large populations; however, the notion of personalizing therapeutic approaches based on various individual patient characteristics is garnering much-deserved attention for optimized practice.
Interventional cardiology is an indispensable unit in myocardial reperfusionological therapy. The growth of this market is characterized by the growth in percutaneous coronary intervention techniques, use of drug-eluting stents and development of catheter based intervention options providing better treatment at minimum invasiveness.
Implementation of telehealth and remote monitoring for management of myocardial ischemia proved to be revolutionary. Remote monitoring cardiac parameters, patient education, virtual consultation is contributing towards integrated care in which improved long term monitoring brings down the burden on hospitals as well as improved long term outcomes.
In the myocardial ischemia market, research and development efforts are ongoing which leads to therapeutic innovations. New drugs that selectively target such pathways associated with ischemic events are being developed and they include the anti platelet agents and anticoagulates which augur well for the patients.
Notably, we see a trend towards ambulatory care models for myocardial ischemia. An outpatient cardiac rehabilitation program, mobile heath apps for self-management, home-based monitoring devices support a more patient-oriented approach improving long-term management and minimize the risk of hospitalization.
As health focus on cardio protection increases the market is focusing more on the strategies that can prevent the onset of ischemia of myocardium. Lifestyle interventions, early l and management of risk factors such as hypertension and hyperlidemia, population-wide education campaigns are all the elements of an integral approach to cardiovascular health.
Joint studies undertaken by the partnerships between academic institutions, pharmaceutical companies, and health care facilities are fueling the comprehension of medical ischemia.
The global expansion of the myocardial ischemia market is evident as healthcare systems worldwide recognize the increasing burden of cardiovascular diseases. Market players are strategically expanding their presence in diverse geographic regions, ensuring accessibility to innovative diagnostics and treatments for a broader population.
Myocardial Ischemia Market Highlights:
Myocardial Ischemia Market Overview
The Myocardial Ischemia Market Size was valued at USD 1.2 Billion in 2023. The Global Myocardial Ischemia industry is projected to grow from USD 1.3 Billion in 2024 to USD 1.5 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.50% during the forecast period (2024 - 2032). Myocardial ischemia is a medical condition characterized by the insufficient blood flow to the heart muscle via coronary arteries, commonly resulting in chest pain. Myocardial ischemia is a medical condition characterized by the insufficient blood flow to the heart muscle via coronary arteries, commonly resulting in chest pain.
Factors such as the high prevalence of coronary heart disease, rising incidence of diabetes, and lifestyle changes provide suitable backgrounds for the development of market growth. However, the high cost of therapeutic surgeries and side effects related to medications are projected to restrain the market growth during the forecast period.
Myocardial Ischemia Market Dynamics
Myocardial ischemia is a common occurrence and occurs with increased frequency in patients with diabetes due to cardiac autonomic dysfunction. According to a study published in the Endocrinology, Diabetes & Metabolism Case Reports journal in 2013, ~22% of the patients diagnosed with type 2 diabetes were estimated to suffer from Silent Myocardial Ischemia (SMI). Moreover, it is reported that the prevalence of diabetes has increased.
This is illustrative by the fact sheet of the World Health Organization (WHO) published in 2017. According to it, the global prevalence of diabetes among individuals ages 18 years or more was about 8.5% in 2014. Thus, it is interpreted that the rising prevalence of diabetes provides a necessary driving force for the myocardial ischemia market to expand.
Myocardial Ischemia Market Segmentation
The myocardial ischemia market has been segmented into type, treatment & diagnosis, and end user. By type, the market has been bifurcated into symptomatic and asymptomatic.
Based on treatment & diagnosis, the market has been divided into diagnosis and treatment. Diagnosis segment has been further segregated into imaging and stress test.
The treatment has been further divided into medications and surgery. By end-user, the market has been classified as hospitals & clinics, diagnostic centers, ambulatory surgery centers, and others. The hospitals and clinics accounted for a market value of USD 18,744.2 million in 2023.
Myocardial Ischemia Market Key Players
The prominent players in the myocardial ischemia market are:
- Taxus Cardium (US)
- ViroMed Co. Ltd. (Republic of Korea )
- Edward Lifesciences (US)
- Daiichi Sankyo Company Limited (Japan)
- Boston Scientific Corporation (US)
- Merck KGaA (Germany)
- Novartis AG (Switzerland)
- Boehringer Ingelheim International GmbH (Germany)
- Johnson & Johnson Services Inc. (US)
- Bayer AG (Germany)
- AstraZeneca (UK)
Some of the key strategies followed by the players operating in the myocardial ischemia market were innovation, product development, acquisition, and expansion.
Myocardial Ischemia Market Regional Analysis
The myocardial ischemia market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is estimated to dominate the brain ischemia ischemiamarket during the forecast period. Americas accounts for the largest regional market owing to the rising prevalence of diabetes, obesity, physical inactivity, and excessive alcohol use among the population.
The European market for myocardial ischemia is expected to be the second-largest during the forecast period. The high growth rate is due to the high incidence rate of cardiovascular diseases in Europe. According to the European Cardiovascular Disease Statistics 2017, 45% of deaths in Europe is due to cardiovascular diseases (CVD).
Additionally, the companies operating in the market are mainly focusing on mergers and acquisition, which is expected to support market growth. Asia-Pacific is estimated to be the fastest-growing market due to the rising prevalence of diabetes. According to the Asian Diabetes Prevention Initiative, 60% of the world’s diabetic patient live in Asia. Such high incidences of diabetes that lead to silent myocardial ischemia are likely to fuel the market growth.
Moreover, in the Asia-Pacific region, China accounted for a market share of 23.5% in 2017. However, the Middle East and Africa are expected to observe slow growth due to less exposure to healthcare services and stringent government rules and regulations.
Key Updates
- In July 2016, Angionetics Inc., a subsidiary of Taxus Cardium, entered into an agreement with Huapont Life Sciences covering a USD 3,000,000 investment, to support the Generx Phase 3 clinical and commercialization development program.
- In February 2018, Edwards Lifesciences Corporation received the CE Mark for its self-expanding CENTERA valve, thus enhancing its transcatheter heart valve therapy segment.
- In August 2017, Boehringer Ingelheim Pharmaceuticals, Inc. received FDA approval for CyltezoTM (adalimumab-adbm).
Market Segmentation
Myocardial Ischemia Market, by Type
- Symptomatic
- Asymptomatic
Myocardial Ischemia Market, by Treatment & Diagnosis
- Diagnosis
- Treatment
Myocardial Ischemia Market, by End User
- Hospitals & Clinics
- Diagnostic Centres
- Ambulatory Surgery Centres
Myocardial Ischemia Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- North America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- Republic of Korea
- Rest of Asia-Pacific
- Middle East & Africa
- United Arab Emirates
- Saudi Arabia
- Oman
- Kuwait
- Qatar
- Rest of The Middle East & Africa
Available Additional Customizations
- Regulatory scenario
Intended Audience
-
- Medical device manufacturers and distributors
- Government research organizations
- Hospitals and clinics
- Regulatory agencies
- Pharmaceutical companies
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
